Alirocumab
Brand names: Praluent Pen
At a glance
- Medicare prescriptions, 2024
- 320,597
- Medicare drug cost
- $237.0M
- Average cost per prescription
- $739
- Clinicians who prescribed it
- 12,170
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
PRALUENT ® is indicated: To reduce the risk of major adverse cardiovascular (CV) events (coronary heart disease death, myocardial infarction, stroke, or unstable angina requiring hospitalization) in adults at increased risk for these events. As an adjunct to diet and exercise to reduce low- density lipoprotein cholesterol (LDL-C) in: adults with hypercholesterolemia. adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). adults with homozygous familial hypercholesterolemia (HoFH).
From the FDA-approved prescribing information (label dated July 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Cardiology 46.0%
- Interventional Cardiology 15.6%
- Nurse Practitioners 13.6%
- Internal Medicine 8.7%
- Family Medicine 5.9%
- Physician Assistants 4.5%
- Endocrinology & Diabetes 1.9%
- Cardiac Electrophysiology 0.7%
- Nuclear Medicine 0.6%
- Heart Failure & Transplant Cardiology 0.6%
- Pharmacists 0.4%
- Nephrology (Kidney) 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 79% from 2019 to 2024.
Biggest change by state since 2019
- North Carolina +138%
- Ohio +132%
- Illinois +130%
- Florida +102%
- Missouri +100%
- Louisiana (smallest change) +14%
- New Jersey (smallest change) +30%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
Drug makers reported $4,979 in payments to clinicians that named this drug in 2025 (meals, speaking, consulting and similar).
- Regeneron Healthcare Solutions, Inc. $4,229
- Sanofi-aventis U.S. LLC $750
Source: CMS Open Payments, general payments (not research), program year 2025. A payment is not evidence of wrongdoing. Payments by doctor
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Industry-funded trials
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.